SCHEDULE: Janus Henderson Boosts Mirum Pharma Stake to 10.6%

Janus Henderson Group plc has disclosed an increased beneficial ownership stake of 10.6% in Mirum Pharmaceuticals, Inc. common stock as of June 30, 2025.

Summary

• Janus Henderson Group plc, a Jersey-based entity, filed an Amendment No. 5 to Schedule 13G regarding its beneficial ownership in Mirum Pharmaceuticals, Inc.
• As of June 30, 2025, Janus Henderson Group plc beneficially owns 5,236,277 shares of Mirum Pharmaceuticals, Inc. common stock.
• This represents 10.6% of the issuer's class of securities.
• The shares are held with shared voting power and shared dispositive power.
• The investment was made in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Indirect subsidiaries, including JHIUS, JHIUKL, and JHIAIFML, are registered investment advisers furnishing investment advice to Managed Portfolios.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of an institutional ownership stake. While not inherently 'positive' or 'negative' in terms of company performance, a significant stake by a reputable asset manager like Janus Henderson can be perceived as a vote of confidence, leaning slightly positive.

Positives

• Janus Henderson Group plc's increased stake to 10.6% may signal confidence from a major institutional investor in Mirum Pharmaceuticals, Inc.

Negatives

• No specific negative information regarding Mirum Pharmaceuticals, Inc. was disclosed in this beneficial ownership filing.

Risks

• This filing is a disclosure of beneficial ownership and does not contain specific risk factors related to Mirum Pharmaceuticals, Inc.'s operations or financial health.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not provide forward-looking statements or guidance regarding Mirum Pharmaceuticals, Inc.'s future performance or strategic direction.

Industry Context

This filing indicates a significant institutional investment in a pharmaceutical company, reflecting ongoing interest from asset managers in the healthcare and biotechnology sectors. Such disclosures are common as large funds adjust their portfolio allocations.

Comparison to Industry Standards

• The 10.6% stake held by Janus Henderson Group plc is a substantial position for an institutional investor in a publicly traded company, indicating a high level of conviction or a significant allocation within their managed portfolios.
• While direct comparable companies or projects are not mentioned, a stake of this size is typically among the larger institutional holdings in a company of Mirum Pharmaceuticals' market capitalization, often placing the investor among the top shareholders.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Janus Henderson Group plc may be viewed positively by other shareholders, potentially signaling confidence in the company's prospects and attracting further investor interest.
• Company Management: Awareness of a large institutional holder like Janus Henderson may influence management's strategic decisions, though the filing states the shares are not held for the purpose of changing or influencing control.

Key Dates

Keywords

Mirum Pharmaceuticals, Janus Henderson, Institutional Ownership, Beneficial Ownership, MRUM, Pharmaceuticals, Investment Management, SEC Filing, Schedule 13G